Echo IQ Announces Investor Webinar on AI-Driven Cardiology Strategy and Progress with Pro Medicus Partnership

Echo IQ’s AI-Enhanced Cardiology Platform and Market Positioning

Based in Sydney, Australia, Echo IQ Limited focuses on enhancing cardiology decision-making through AI-powered technology and proprietary software. The company targets clinical challenges in cardiology, integrating AI innovations to support diagnostic and treatment planning. This focus places Echo IQ at the forefront of healthcare AI innovation, addressing critical needs within cardiac care.

Echo IQ’s specialised approach differentiates it within the broader medical technology and healthcare AI sectors. By concentrating on cardiology-specific applications, the company has developed proprietary solutions designed to seamlessly integrate into clinical workflows. This targeted expertise enables deep engagement with cardiology professionals and healthcare institutions, positioning Echo IQ as a key player in cardiac imaging and assessment technology.

Strategic Partnership with Pro Medicus and Market Growth Opportunities

Echo IQ’s recently announced strategic partnership with Pro Medicus Limited (ASX:PME), a prominent medical imaging software provider, marks a significant step in expanding market reach. Pro Medicus offers established distribution networks across multiple healthcare systems, complementing Echo IQ’s AI cardiology focus. This collaboration aims to combine Echo IQ’s innovative technology with Pro Medicus’s market infrastructure to accelerate commercialisation and adoption.

The partnership reflects Echo IQ’s multi-faceted commercial strategy to build market presence and revenue streams by leveraging established healthcare technology channels. Although specific terms and revenue-sharing details remain undisclosed, this alliance is expected to enhance Echo IQ’s access to customers, regulatory expertise, and commercial capabilities. Investors will likely seek further insights into the partnership’s impact on growth during the upcoming webinar.

Binding Term Sheet with Advara HeartCare and Commercial Expansion

Echo IQ has formalised a binding term sheet with Advara HeartCare, marking progress toward revenue-generating partnerships. This agreement signifies a commitment to specific commercial terms, advancing beyond preliminary discussions to formalised engagement with a cardiac healthcare provider. The term sheet underscores market validation of Echo IQ’s technology from a provider perspective.

While financial details and implementation timelines were not disclosed, this development indicates movement toward customer acquisition and revenue generation. The term sheet follows extensive evaluation of clinical integration, pricing, and operational feasibility. Additional details are expected during the investor webinar.

Progress on EchoSolv HF FDA 510(k) Submission and Regulatory Milestones

Echo IQ continues to advance the EchoSolv HF product through the FDA 510(k) clearance process, a critical regulatory step for US market authorisation. This pathway allows medical devices substantially equivalent to existing products to gain approval for commercialisation. Progress in this submission demonstrates ongoing regulatory engagement and positions Echo IQ to enter the substantial US healthcare market upon clearance.

The company has not provided specific timelines or technical details regarding the FDA review. Given the complexity of regulatory processes, timelines may extend over months or years. The upcoming webinar may offer further updates on regulatory progress and anticipated milestones. FDA clearance would be a pivotal achievement enabling US commercialisation.

Institutional Placement Completion Strengthens Capital Base

Echo IQ has completed an institutional placement, raising capital from professional investors to support operational and strategic initiatives. Although the placement’s size, share pricing, and participant details were not disclosed, this funding round signals institutional confidence in Echo IQ’s growth trajectory and market potential.

The capital raised is expected to fuel product development, regulatory submissions, and commercial expansion efforts aligned with recent operational milestones. Further information on the placement may be shared during the investor webinar or future communications.

Leadership Update: Appointment of CFO Matthew Dodds

Echo IQ has appointed Matthew Dodds as Chief Financial Officer, enhancing the company’s financial leadership amid growth and increasing operational complexity. Mr. Dodds will oversee financial management, reporting, capital allocation, and investor relations. His involvement in the upcoming webinar alongside CEO Dustin Haines highlights his integral role in the company’s strategic communications.

This appointment reflects Echo IQ’s transition toward a more mature operational phase, managing multiple revenue streams, partnerships, and regulatory compliance. The CFO role is critical in guiding financial strategy and stakeholder engagement as the company advances its commercialisation efforts.

Investor Webinar Details and Participation Information

The investor webinar is scheduled for Thursday, 30 July 2026, at 11:00am (AEST). Registration is available via a Zoom link provided by Echo IQ. CEO Dustin Haines and CFO Matthew Dodds will present updates on operational progress, commercial strategy, and future priorities. A live Q&A session will follow, allowing shareholders to submit questions in advance via [email protected] or [email protected], or during the event.

The webinar will be recorded and accessible on Echo IQ’s website post-event, enabling shareholders unable to attend live to review the presentation. For assistance, shareholders can contact Henry Jordan of Six Degrees Investor Relations at [email protected] or +61 (0) 431 271 538.

Commercial Strategy and Future Priorities

During the webinar, Echo IQ’s management will outline the company’s commercial strategy, linking recent partnerships, agreements, and regulatory progress to a broader revenue-generation roadmap. The strategy focuses on leveraging AI cardiology technology alongside established healthcare infrastructure to accelerate market adoption. Specific revenue targets and growth projections were not disclosed in this announcement.

Management is expected to discuss plans to convert regulatory approvals and partnerships into commercial success, navigating the complexities of healthcare technology adoption. The webinar offers shareholders an opportunity to gain insights into competitive positioning, capital deployment, and strategic priorities. Investors are encouraged to submit questions about revenue expectations, profitability timelines, and market assumptions.

Healthcare AI Sector Dynamics and Industry Drivers

Echo IQ operates within the rapidly growing healthcare AI and medical technology sector, driven by increasing demand for AI-enabled diagnostic tools. Cardiology faces specialist shortages and high demand for diagnostic accuracy, creating opportunities for AI-assisted solutions. Regulatory frameworks, including the FDA’s 510(k) pathway, are evolving to support AI medical devices, facilitating market entry.

Capital availability from institutional and venture investors is rising, recognising the commercial potential of validated AI healthcare solutions. Integration of AI into clinical workflows is becoming essential for improving efficiency and outcomes. Echo IQ’s proprietary AI cardiology platform and partnerships with firms like Pro Medicus demonstrate market validation and alignment with these sector trends.

Risks and Market Adoption Challenges

Investors should consider risks inherent in medical technology and healthcare AI commercialisation. Adoption by healthcare providers typically involves extended timelines due to clinical validation, regulatory approvals, and integration challenges. The EchoSolv HF FDA 510(k) submission remains subject to regulatory review with potential delays or additional requirements. Competition in cardiology AI is intensifying, potentially impacting market share and pricing power.

Additional risks include regulatory and reimbursement uncertainties, data privacy and cybersecurity compliance, and dependency on strategic partnerships such as with Pro Medicus. Market adoption may be hindered by workflow disruptions or institutional conservatism. The investor webinar will be an opportunity for management to address strategies for mitigating these risks and advancing market penetration.